IL261959B2 - Treatment of cancer with tg02 - Google Patents

Treatment of cancer with tg02

Info

Publication number
IL261959B2
IL261959B2 IL261959A IL26195918A IL261959B2 IL 261959 B2 IL261959 B2 IL 261959B2 IL 261959 A IL261959 A IL 261959A IL 26195918 A IL26195918 A IL 26195918A IL 261959 B2 IL261959 B2 IL 261959B2
Authority
IL
Israel
Prior art keywords
cancer
inhibitor
patient
protein
receptor
Prior art date
Application number
IL261959A
Other languages
English (en)
Hebrew (he)
Other versions
IL261959B1 (en
IL261959A (en
Original Assignee
Adastra Pharmaceuticals Inc
Cothera Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adastra Pharmaceuticals Inc, Cothera Bioscience Inc filed Critical Adastra Pharmaceuticals Inc
Publication of IL261959A publication Critical patent/IL261959A/en
Publication of IL261959B1 publication Critical patent/IL261959B1/en
Publication of IL261959B2 publication Critical patent/IL261959B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL261959A 2016-03-24 2018-09-26 Treatment of cancer with tg02 IL261959B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US201662423468P 2016-11-17 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Publications (3)

Publication Number Publication Date
IL261959A IL261959A (en) 2018-10-31
IL261959B1 IL261959B1 (en) 2023-04-01
IL261959B2 true IL261959B2 (en) 2023-08-01

Family

ID=59899752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261959A IL261959B2 (en) 2016-03-24 2018-09-26 Treatment of cancer with tg02

Country Status (12)

Country Link
US (2) US11865116B2 (cg-RX-API-DMAC7.html)
EP (1) EP3432888B1 (cg-RX-API-DMAC7.html)
JP (2) JP7026299B2 (cg-RX-API-DMAC7.html)
KR (2) KR102491013B1 (cg-RX-API-DMAC7.html)
CN (2) CN115969854B (cg-RX-API-DMAC7.html)
AU (1) AU2017238647B2 (cg-RX-API-DMAC7.html)
ES (1) ES2941687T3 (cg-RX-API-DMAC7.html)
IL (1) IL261959B2 (cg-RX-API-DMAC7.html)
MX (3) MX2021012977A (cg-RX-API-DMAC7.html)
RU (1) RU2749025C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202005621WA (cg-RX-API-DMAC7.html)
WO (1) WO2017165732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
MX2021011301A (es) * 2019-03-18 2022-01-19 Univ Texas Terapia combinada especifica contra tumores.
ES3034869T3 (en) * 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2022035723A1 (en) * 2020-08-10 2022-02-17 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
MX2024006078A (es) * 2021-11-18 2024-08-09 Lantern Pharma Inc Metodo para tratar el cancer con acilfulveno y radiacion.
CN114113051B (zh) * 2021-12-16 2023-06-16 南京信息工程大学 一种psma电致化学发光传感器的制备方法及应用
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (zh) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 新靶点用于诊断和治疗垂体腺瘤
WO2023143608A1 (zh) * 2022-01-30 2023-08-03 上海复东生物医药有限责任公司 一种组合物、其制备方法及应用
CN114518456B (zh) * 2022-02-17 2025-06-20 南京医科大学 一种通过diaph1蛋白预测肿瘤免疫治疗疗效的方法及试剂盒
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153870A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
US9120815B2 (en) * 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
WO2014011695A2 (en) * 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
JP6767875B2 (ja) 2014-04-08 2020-10-14 ライジェル ファーマシューティカルズ, インコーポレイテッド Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153870A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOFMEISTER ET AL.,, TG02, AN ORAL CDK9-INHIBITOR, IN COMBINATION WITH CARFILZOMIB DEMONSTRATED OBJECTIVE RESPONSES IN CARFILZOMIB REFRACTORY MULTIPLE MYELOMA PATIENTS, 31 December 2015 (2015-12-31) *
S. ALVAREZ-FERNANDEZ ET AL,, POTENT ANTIMYELOMA ACTIVITY OF A NOVEL ERK5/CDK INHIBITOR, 15 May 2013 (2013-05-15) *

Also Published As

Publication number Publication date
EP3432888B1 (en) 2022-10-05
MX387283B (es) 2025-03-18
CA3018875A1 (en) 2017-09-28
KR20190006948A (ko) 2019-01-21
RU2749025C2 (ru) 2021-06-03
IL261959B1 (en) 2023-04-01
IL261959A (en) 2018-10-31
WO2017165732A1 (en) 2017-09-28
JP7459149B2 (ja) 2024-04-01
AU2017238647B2 (en) 2021-12-09
SG10202005621WA (en) 2020-07-29
RU2018137217A3 (cg-RX-API-DMAC7.html) 2020-05-29
US11865116B2 (en) 2024-01-09
CN115969854B (zh) 2025-12-23
SG11201808306PA (en) 2018-10-30
MX2021012977A (es) 2022-10-03
RU2018137217A (ru) 2020-04-24
ES2941687T3 (es) 2023-05-24
JP2019509354A (ja) 2019-04-04
MX2022008868A (es) 2022-08-11
AU2017238647A1 (en) 2018-10-25
JP2022050631A (ja) 2022-03-30
EP3432888A1 (en) 2019-01-30
EP3432888A4 (en) 2019-11-13
NZ746933A (en) 2025-03-28
KR102491013B1 (ko) 2023-01-31
US20200323862A1 (en) 2020-10-15
CN115969854A (zh) 2023-04-18
CN109195603B (zh) 2022-11-08
CN109195603A (zh) 2019-01-11
JP7026299B2 (ja) 2022-02-28
US20240156824A1 (en) 2024-05-16
KR20230020549A (ko) 2023-02-10

Similar Documents

Publication Publication Date Title
US20240156824A1 (en) Treatment of cancer with tg02
US20240254141A1 (en) Polymorphic form of tg02 for treating cancer
MX2010008572A (es) Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa.
Hung et al. Histiocytic sarcoma: new insights into FNA cytomorphology and molecular characteristics
CA3018875C (en) Treatment of cancer with tg02
US20240139175A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
HK40106713A (en) Polymorphic form of tg02
HK40025378B (en) Polymorphic form of tg02
HK40025378A (en) Polymorphic form of tg02
JP6312861B2 (ja) がん発症の予測、早期診断、及び治療剤としてのnkx6.3の用途
HK1261788A1 (en) Treatment of cancer with tg02
HK1261788B (en) Treatment of cancer with tg02
Cai et al. Arsenic Sulfide EnhancesRadiosensitization in Rhabdomyosarcoma via Activating NFATc3-RAG1 Mediated DNA Double Strand Break (DSB)
Kurimoto et al. MYC/BCL2 double-hit Lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment